Zaltoprofen

Cat. No.:	HY-B0619		
CAS No.:	74711-43-6		
Molecular Formula:	C ₁₇ H ₁₄ O ₃ S		
Molecular Weight:	298.36		
Target:	COX		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year


SOLVENT & SOLUBILITY

Preparing Stock Solutions Please refer to the so		Solvent Mass	1 mg	5 mg	10 mg	
		Concentration 1 mM	3.3517 mL	16.7583 mL	33.5166 mL	
	5 mM	0.6703 mL	3.3517 mL	6.7033 mL		
		10 mM	0.3352 mL	1.6758 mL	3.3517 mL	
	Please refer to the solubility information to select the appropriate solvent.					
Vivo		t one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline mg/mL (8.38 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active COX-2 inhibitor, with IC ₅₀ s of 1.3 and 0.34 μM for COX-1 and COX-2, respectively. Zaltoprofen exhibits powerful anti-inflammatory effects as well as an analgesic action on inflammatory pain ^{[1][2][3]} .	
IC₅₀ & Target	COX-2 0.34 μM (IC ₅₀)	COX-1 1.3 μM (IC ₅₀)

Product Data Sheet





In Vitro	Zaltoprofen (0.1-10 μM; 15 min) inhibits thromboxane B2 production in human platelets in a dose-dependent manner ^[1] . Zaltoprofen (0.01-1 μM; 30 min) inhibits prostaglandin E2 production by interleukin-1β-stimulated synovial cells ^[1] . Zaltoprofen (0.1-1 μM; 5 min) inhibits the bradykinin-induced increase of [Ca ²⁺] _i in DRG cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Zaltoprofen (5-20 mg/kg; a single p.o.) inhibits bradykinin-induced nociceptive responses in rats ^[2] . Zaltoprofen (3-30 mg/kg; a single p.o.) inhibits the acetic acid-induced writhing response of mice in a dose-dependent manner ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Eight-week-old male Wistar rats were injected Bradykinin every 15 min ^[2] Dosage: 5, 10, 20 mg/kg		
	Administration:	A single p.o.	
	Result:	Inhibited bradykinin-induced nociceptive responses, with an ED50 of 9.7 mg/kg. The duration of analgesic effect was 60-90 min.	

REFERENCES

[1]. Kawai S, et, al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94.

[2]. Hirate K, et, al. Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94.

[3]. Kameyama T, et, al. Analgesic and antiinflammatory effects of 2-(10,11-dihydro-10-oxo-dibenzo[b,f]thiepin-2-yl)propionic acid in rat and mouse. Arzneimittelforschung. 1987 Jan;37(1):19-26.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA